PsychedelicNewsBreaks – MagicMed Industries Inc. Announces First Psychedelic Derivative Patent Filing in Anticipated Series

MagicMed Industries today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (“USPTO”) covering composition of matter, drug formulation and process of preparation claims for novel psilocybin derivatives. According to the update, the patent filing is anticipated to be the first in a series of applications that together will protect the Company’s broad portfolio of novel psilocybin molecular derivatives, the “PsybraryTM.” “We are excited by the new opportunities to partner with pharmaceutical manufacturers afforded by the library of derivatives that this patent application claims,” MagicMed CEO and President, Dr. Joseph Tucker, stated in the news release. “Our business model is to work hand in hand with pharma partners to assist them in taking excellent medicinal product candidates forward.  In fact, we have already initiated talks with potential partners to assist them in the development of new therapies for diverse psychological indications.”

To view the full press release, visit http://ibn.fm/NU0ch

About MagicMed

MagicMed Industries intends to partner with pharmaceutical and other companies to develop psychedelic-derived medicinal and licit consumer goods products.  MagicMed’s molecular derivatives library, the PsybraryTM is anticipated to be an essential building block from which industry can develop new patented products.  The initial focus of the PsybraryTM is on psilocybin, which is expected to be opportunistically expanded to other psychedelics like MDMA, ketamine, Ibogaine, Mescaline, and Ayahuasca.  For more information, please visit www.MagicMedIndustries.com.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.